BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tris Pharma, Inc. Announces Approval of First-Ever Generic of Tussionex(R) Extended-Release Suspension


10/7/2010 6:31:49 AM

MONMOUTH JUNCTION, N.J., Oct. 7 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the US Food and Drug Administration (FDA) has approved first-ever generic of TUSSIONEX®, an Extended-Release Suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

Tussionex was approved in the 1980's based on 1970's technology involving organic solvent based coatings. Based on its highly versatile, patent-pending technology, OralXR+, Tris' products avoid use of toxic organic solvents by employing an aqueous based coating system. Tris pioneered the delivery of taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are traditionally associated with immediate release.

"This approval, on the back of our 2009 NDA approval for the first ever 24-hour controlled release liquid product, extends Tris' strong track record," said Ketan Mehta, President & CEO of Tris Pharma. "Tris' R&D team and engineers have not only developed a number of innovative products but also created a large, scalable manufacturing infrastructure with ample capacity to supply generic Tussionex along with our branded portfolio."

Par Pharmaceutical has begun the shipment of the Tris product under an exclusive distribution agreement. Annual U.S. sales of Tussionex® are approximately $226 million, according to IMS Health data.

About Tris Pharma:

Tris Pharma is a specialty pharmaceutical company focused on drug delivery technologies based products including difficult-to-formulate or complex generic products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey.

For more information visit http://www.trispharma.com

Tussionex is a trademark of UCB Manufacturing, Inc., which has no affiliation with or connection to Tris Pharma.

SOURCE Tris Pharma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES